BOOST: CNS Tumor Board—Case-based Review of MR Imaging and Treatment Management for the Radiologist and Radiation Oncologist (An Interactive Session)

MSRO43

BOOST: CNS Tumor Board—Case-based Review of MR Imaging and Treatment Management for the Radiologist and Radiation Oncologist (An Interactive Session)

Multisession Courses — Neuroradiology, Magnetic Resonance Imaging, Oncologic Imaging, Radiation Oncology,

Presented on December 3, 2014

Christina I. Tsien MD, Presenter: Nothing to Disclose

Whitney B. Pope MD, PhD, Presenter: Research Consultant, F. Hoffmann-La Roche Ltd Research Consultant, Amgen Inc Research Consultant, Tocagen Inc Consultant, Celldex Therapeutics, Inc Consultant, Guerbet SA

Michael Vogelbaum MD, Presenter: Stockholder, Infuseon Therapeutics, Inc

Patrick Y. Wen MD, Presenter: Research Consultant, F. Hoffmann-La Roche Ltd

1) Describe the imaging characteristics of gliomas and other brain tumors. 2) Recognize the substantial heterogeneity that exists within these tumor types and understand the prognostic and predictive variables that allow for the appropriate selection of therapeutic choices. 3) Explain the role of each modality including surgery, radiotherapy and chemotherapy in managing these tumors.

Significant progress has been made in the treatment of CNS tumors with an emphasis on molecular prognostic and predictive biomarkers that allow for the selection of appropriate patient specific treatment. In this case-based panel discussion, each discussant will present a challenging CNS case, highlighting the need for a multi-disciplinary treatment approach. The role of neuro-imaging to help clinicians improve the diagnosis, treatment and response assessment for CNS tumors will be emphasized. Statement References: 1. Cairncross G, Wang M, Shaw E, et al: Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337-343, 2013 2. van den Bent MJ, Brandes AA, Taphoorn MJ, et al: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol 31: 344-350, 2013 3. Rohle D, Popovici-Muller J, Palaskas N, et al: An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626-630, 2013

Tsien, C, Pope, W, Vogelbaum, M, Wen, P, BOOST: CNS Tumor Board—Case-based Review of MR Imaging and Treatment Management for the Radiologist and Radiation Oncologist (An Interactive Session). Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14002288.html